Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Aug 1:16:1604987.
doi: 10.3389/fimmu.2025.1604987. eCollection 2025.

Immunological microenvironment and targeted therapeutics in multiple sclerosis: new insights in crosstalk between immune niches and CNS

Affiliations
Review

Immunological microenvironment and targeted therapeutics in multiple sclerosis: new insights in crosstalk between immune niches and CNS

Xiaodi Sun et al. Front Immunol. .

Abstract

Multiple sclerosis (MS) is a chronic autoimmune disorder of the central nervous system (CNS) that predominantly affects young adults. However, current disease-modifying therapies demonstrate limited efficacy in addressing progressive disease subtypes, underscoring the urgent need for novel therapeutic strategies. Here, we systematically review the neuroimmune interactions underlying the pathogenesis of MS, with a focus on three key aspects: the immune niche, immune cell types, and cell-based therapies. We first discuss the evolution of brain-immune concepts, from early notions of immune privilege to modern understandings of brain-border immune niches (meninges, choroid plexus, and perivascular spaces). These compartments serve as critical interfaces where peripheral immune cells interact with CNS-resident immune cells. We then analyze the roles of specific immune cell subsets (e.g., T/B cells, myeloid cells and microglia) in disease progression, highlighting their functional heterogeneity across different MS subtypes. Furthermore, we highlight emerging MS immunotherapies-including chimeric antigen receptor (CAR) T regimens, mesenchymal stem cell interventions, microbiome modulation, and nanodelivery systems, which strategically target mechanistic nodes spanning neuroimmune niche regulation, inflammatory cascade blockade, and CNS neurorestorative capacities.

Keywords: autoimmune; cerebral immune niches; multiple sclerosis; neuroimmune; targeted therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Overview of the pathogenesis of cerebral immune niches in Multiple Sclerosis and their interactions with other systems. Created in BioRender. Xiaodi, S. (2025) https://BioRender.com/a6k520m.
Figure 2
Figure 2
The mechanistic framework of marketed immune-targeting therapeutics for multiple sclerosis encompasses: orchestrating lymphocyte polarization, suppressing pathogenic Th17/Treg imbalance, enforcing CNS infiltration blockade via endothelial adhesion modulation, and stimulating oligodendrocyte-mediated remyelination. Figure created with Adobe Illustrator.

Similar articles

References

    1. Reich DS, Lucchinetti CF, Calabresi PA. Multiple sclerosis. New Engl J Med. (2018) 378:169–80. doi: 10.1056/nejmra1401483, PMID: - DOI - PMC - PubMed
    1. Sejvar J. H1 Connect Recommendation of GBD 2015 Neurological Disorders Collaborator Group. Lancet Neurol. 16(11:877-897)]. In H1 Connect. (2018). doi: 10.3410/f.731253574.793550809 - DOI - PMC - PubMed
    1. Wallin MT, Culpepper WJ, Campbell JD, Nelson LM, Langer-Gould A, Marrie RA, et al. The prevalence of MS in the United States. Neurology. (2019) 92:e1029–40. doi: 10.1212/wnl.0000000000007035, PMID: - DOI - PMC - PubMed
    1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. New Engl J Med. (2000) 343:938–52. doi: 10.1056/nejm200009283431307, PMID: - DOI - PubMed
    1. Sawcer S, Franklin RJM, Ban M. Multiple sclerosis genetics. Lancet Neurology. (2014) 13:700–9. doi: 10.1016/s1474-4422(14)70041-9, PMID: - DOI - PubMed

LinkOut - more resources